Until recently, APOE genotyping was not regularly used or recommended by most neurologists, since there was no known way to prevent the effects of Alzheimer’s disease. However, new research indicates that cognitive decline can be delayed or even prevented with proper nutrition, sleep, exercise, and rigorous intellectual activity. Moreover, development of Alzheimer’s therapies is rapidly advancing, and some clinical trials now require APOE results to qualify.
Consider testing for ApoE ε4 status to inform the risk of developing ARIA (amyloid-related imaging abnormalities) when deciding to initiate treatment with LEQEMBI.